uniQure's AMT-130 Gene Therapy Warrants An Upgrade

Company Overview - uniQure N.V. is a gene therapy company with four clinical programs and several data catalysts expected in 2025 and 2026 [1] - The flagship candidate of the company is AMT-130, which has received several FDA designations including Breakthrough Therapy, RMAT, Fast-Track, and Orphan Drug [1] Clinical Programs - The company is actively working on its clinical programs, with a focus on advancing its lead candidate AMT-130 [1]